Bisphosphonates  ||| S:0 E:16 ||| NNP
and  ||| S:16 E:20 ||| CC
atherosclerosis  ||| S:20 E:36 ||| VBG
The  ||| S:36 E:40 ||| DT
relevance  ||| S:40 E:50 ||| NN
of  ||| S:50 E:53 ||| IN
association  ||| S:53 E:65 ||| NN
between  ||| S:65 E:73 ||| IN
osteoporosis  ||| S:73 E:86 ||| NN
and  ||| S:86 E:90 ||| CC
cardiovascular  ||| S:90 E:105 ||| JJ
disease  ||| S:105 E:113 ||| NN
in  ||| S:113 E:116 ||| IN
clinical  ||| S:116 E:125 ||| JJ
settings ||| S:125 E:133 ||| NNS
,  ||| S:133 E:135 ||| ,
and  ||| S:135 E:139 ||| CC
the  ||| S:139 E:143 ||| DT
evidence  ||| S:143 E:152 ||| NN
of  ||| S:152 E:155 ||| IN
a  ||| S:155 E:157 ||| DT
biological  ||| S:157 E:168 ||| JJ
linkage  ||| S:168 E:176 ||| NN
between  ||| S:176 E:184 ||| IN
bone  ||| S:184 E:189 ||| NN
and  ||| S:189 E:193 ||| CC
vascular  ||| S:193 E:202 ||| JJ
calcification ||| S:202 E:215 ||| NN
,  ||| S:215 E:217 ||| ,
encourage  ||| S:217 E:227 ||| VB
the  ||| S:227 E:231 ||| DT
search  ||| S:231 E:238 ||| NN
of  ||| S:238 E:241 ||| IN
drugs  ||| S:241 E:247 ||| NNS
that  ||| S:247 E:252 ||| WDT
may  ||| S:252 E:256 ||| MD
act  ||| S:256 E:260 ||| VB
as  ||| S:260 E:263 ||| IN
dual-purpose  ||| S:263 E:276 ||| JJ
therapies ||| S:276 E:285 ||| NNS
,  ||| S:285 E:287 ||| ,
concordantly  ||| S:287 E:300 ||| FW
enhancing  ||| S:300 E:310 ||| FW
bone  ||| S:310 E:315 ||| FW
density  ||| S:315 E:323 ||| FW
and  ||| S:323 E:327 ||| CC
reducing  ||| S:327 E:336 ||| VBG
atherosclerosis ||| S:336 E:351 ||| NNS
.  ||| S:351 E:353 ||| .
Bisphosphonates  ||| S:353 E:369 ||| NNP
( ||| S:369 E:370 ||| -LRB-
BP ||| S:370 E:372 ||| NNP
)  ||| S:372 E:374 ||| -RRB-
reduce  ||| S:374 E:381 ||| VB
bone  ||| S:381 E:386 ||| JJ
resorption  ||| S:386 E:397 ||| NN
and  ||| S:397 E:401 ||| CC
fracture  ||| S:401 E:410 ||| JJ
risk ||| S:410 E:414 ||| NN
,  ||| S:414 E:416 ||| ,
and  ||| S:416 E:420 ||| CC
also  ||| S:420 E:425 ||| RB
seem  ||| S:425 E:430 ||| VB
to  ||| S:430 E:433 ||| TO
have  ||| S:433 E:438 ||| VB
the  ||| S:438 E:442 ||| DT
potential  ||| S:442 E:452 ||| JJ
to  ||| S:452 E:455 ||| TO
reduce  ||| S:455 E:462 ||| VB
atherosclerotic  ||| S:462 E:478 ||| JJ
process ||| S:478 E:485 ||| NN
.  ||| S:485 E:487 ||| .
This  ||| S:487 E:492 ||| DT
unexpected  ||| S:492 E:503 ||| JJ
activity  ||| S:503 E:512 ||| NN
is  ||| S:512 E:515 ||| VBZ
the  ||| S:515 E:519 ||| DT
result  ||| S:519 E:526 ||| NN
of  ||| S:526 E:529 ||| IN
their  ||| S:529 E:535 ||| PRP$
interference  ||| S:535 E:548 ||| NN
with  ||| S:548 E:553 ||| IN
cholesterol  ||| S:553 E:565 ||| NN
synthesis ||| S:565 E:574 ||| NN
,  ||| S:574 E:576 ||| ,
inflammatory  ||| S:576 E:589 ||| JJ
progression ||| S:589 E:600 ||| NN
,  ||| S:600 E:602 ||| ,
and  ||| S:602 E:606 ||| CC
oxidative  ||| S:606 E:616 ||| JJ
stress ||| S:616 E:622 ||| NN
.  ||| S:622 E:624 ||| .
Although  ||| S:624 E:633 ||| IN
most  ||| S:633 E:638 ||| JJS
animal  ||| S:638 E:645 ||| NN
studies  ||| S:645 E:653 ||| NNS
show  ||| S:653 E:658 ||| VBP
a  ||| S:658 E:660 ||| DT
clear  ||| S:660 E:666 ||| JJ
anti-atherogenic  ||| S:666 E:683 ||| JJ
activity  ||| S:683 E:692 ||| NN
of  ||| S:692 E:695 ||| IN
BP ||| S:695 E:697 ||| NNP
,  ||| S:697 E:699 ||| ,
data  ||| S:699 E:704 ||| NNS
in  ||| S:704 E:707 ||| IN
humans  ||| S:707 E:714 ||| NNS
are  ||| S:714 E:718 ||| VBP
not  ||| S:718 E:722 ||| RB
consistent  ||| S:722 E:733 ||| JJ
or  ||| S:733 E:736 ||| CC
conclusive ||| S:736 E:746 ||| NN
,  ||| S:746 E:748 ||| ,
given  ||| S:748 E:754 ||| VBN
the  ||| S:754 E:758 ||| DT
high  ||| S:758 E:763 ||| JJ
affinity  ||| S:763 E:772 ||| NN
of  ||| S:772 E:775 ||| IN
BP  ||| S:775 E:778 ||| NNP
for  ||| S:778 E:782 ||| IN
bone ||| S:782 E:786 ||| NN
,  ||| S:786 E:788 ||| ,
which  ||| S:788 E:794 ||| WDT
prevents  ||| S:794 E:803 ||| VBZ
them  ||| S:803 E:808 ||| PRP
from  ||| S:808 E:813 ||| IN
accumulating  ||| S:813 E:826 ||| VBG
in  ||| S:826 E:829 ||| IN
other  ||| S:829 E:835 ||| JJ
tissues  ||| S:835 E:843 ||| NNS
at  ||| S:843 E:846 ||| IN
the  ||| S:846 E:850 ||| DT
concentration  ||| S:850 E:864 ||| NN
required  ||| S:864 E:873 ||| VBN
to  ||| S:873 E:876 ||| TO
exert  ||| S:876 E:882 ||| VB
a  ||| S:882 E:884 ||| DT
clear  ||| S:884 E:890 ||| JJ
pharmacological  ||| S:890 E:906 ||| JJ
effect ||| S:906 E:912 ||| NN
.  ||| S:912 E:914 ||| .
